Open in Screener

TECX

Tectonic Therapeutic Inc

Aug 18 • 04:00PM ET

24.71

Dollar change +1.20
Percentage change 5.10	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN AMGN GILD BIIB BMRN INCY EXEL NBIX RGEN

| Held by: VTI IWM VXF IWN IBB VTWO IWC IWO DFAS BBC

Index	RUT	P/E	-	EPS (ttm)	-4.04	Insider Own	43.26%	Shs Outstand	18.71M	Perf Week	11.76%
Market Cap	462.37M	Forward P/E	-	EPS next Y	-4.79	Insider Trans	1.78%	Shs Float	10.59M	Perf Month	12.78%
Enterprise Value	176.93M	PEG	-	EPS next Q	-1.06	Inst Own	61.19%	Short Float	20.52%	Perf Quarter	17.72%
Income	-65.98M	P/S	-	EPS this Y	38.78%	Inst Trans	48.44%	Short Ratio	9.98	Perf Half Y	-30.53%
Sales	0.00M	P/B	1.63	EPS next Y	-14.56%	ROA	-26.97%	Short Interest	2.17M	Perf YTD	-46.48%
Book/sh	15.16	P/C	1.61	EPS next 5Y	5.74%	ROE	-29.32%	52W High	61.07 -59.54%	Perf Year	53.86%
Cash/sh	15.36	P/FCF	-	EPS past 3/5Y	41.06% 26.54%	ROIC	-23.24%	52W Low	13.70 80.36%	Perf 3Y	98.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.84% 6.99%	Perf 5Y	-87.92%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	71.85%	Oper. Margin	-	ATR (14)	1.58	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	25.60	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	61.36	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	25.60	EPS Q/Q	75.35%	SMA20	9.80%	Beta	1.52	Target Price	79.71
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	12.79%	Rel Volume	0.58	Prev Close	23.51
Employees	51	LT Debt/Eq	0.00	Earnings	Aug 07 AMC	SMA200	-17.58%	Avg Volume	217.63K	Price	24.71
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.47% -	Trades		Volume	125,944	Change	5.10%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-25	Initiated	Truist	Buy	$64
Jun-11-25	Resumed	Raymond James	Outperform	$76
Apr-21-25	Initiated	Mizuho	Outperform	$51
Nov-20-24	Initiated	Raymond James	Outperform	$65
Aug-22-24	Initiated	Wells Fargo	Overweight	$55
Jun-26-24	Initiated	Piper Sandler	Overweight
Jun-24-24	Initiated	TD Cowen	Buy
Dec-18-23	Downgrade	Mizuho	Buy → Neutral
Jan-05-22	Downgrade	BTIG Research	Buy → Neutral
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$24 → $7
Jun-15-21	Initiated	BTIG Research	Buy	$23
May-27-21	Initiated	Needham	Buy	$28
Mar-09-21	Initiated	Barclays	Overweight	$23
Mar-02-21	Initiated	Stifel	Hold	$14
Nov-11-20	Initiated	Berenberg	Buy
Mar-31-20	Downgrade	H.C. Wainwright	Buy → Neutral	$13
Jun-27-19	Initiated	Mizuho	Buy	$28
Apr-05-19	Initiated	Janney	Buy
Oct-10-18	Initiated	Guggenheim	Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$47 → $40

Show Previous Ratings

Aug-07-25 04:01PM	Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -5.35%
Jun-30-25 08:00AM	Tectonic Therapeutic Joins Russell 3000 Index (GlobeNewswire)
Jun-24-25 05:42PM	Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating (Insider Monkey) +7.57%
May-17-25 10:40AM	Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 (GlobeNewswire)
May-13-25 09:55AM	Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High? (Zacks)
04:01PM	Loading…
May-08-25 04:01PM	Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +10.81% -5.99%
May-07-25 08:00AM	Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference (GlobeNewswire)
May-01-25 05:59AM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks Earning Wall Streets Seal of Approval (TipRanks) -5.75%
Apr-23-25 05:51AM	Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF (Seeking Alpha)
Apr-15-25 08:00AM	Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025 (GlobeNewswire)
Mar-20-25 04:01PM	Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-04-25 08:26PM	Is Tectonic Therapeutic, Inc. (TECX) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Feb-20-25 08:00AM	Tectonic Therapeutic to Participate in March Investor Conferences (GlobeNewswire)
Feb-03-25 06:30AM	Tectonic Announces $185 Million Private Placement (GlobeNewswire) -6.52%
Jan-30-25 06:30AM	Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF (GlobeNewswire) +113.22%
04:01PM	Loading…
Dec-03-24 04:01PM	Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024 (GlobeNewswire)
Nov-26-24 04:01PM	Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-12-24 11:01PM	Tectonic Therapeutic Inc. Reports Q3 2024 Results (TipRanks)
Nov-11-24 05:00AM	Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein (GlobeNewswire)
Nov-07-24 04:01PM	Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-22-24 04:01PM	Tectonic Therapeutic to Present Phase 1a Data at AHA 2024 (GlobeNewswire)
Sep-19-24 04:01PM	Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 (GlobeNewswire)
Aug-20-24 04:01PM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-24 04:01PM	Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +5.23%
Jul-30-24 04:01PM	Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45 (GlobeNewswire)
Jun-20-24 04:01PM	Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million (Business Wire)
09:47AM	PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML (InvestorPlace)
08:26AM	Why Is Avrobio (AVRO) Stock Moving Today? (InvestorPlace)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-15-24 11:27AM	Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing (MT Newswires) +6.20%
09:53AM	Loading…
May-13-24 09:53AM	AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024 (InvestorPlace) +9.76%
Feb-27-24 10:50AM	Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm (PR Newswire)
Feb-01-24 02:25PM	Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm (PR Newswire)
Jan-31-24 10:40AM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TAST, AVRO, CALB (GlobeNewswire) +9.57%
06:42AM	Avrobios road ends in reverse merger with Tim Springer-backed startup (BioPharma Dive)
Jan-30-24 02:52PM	Avrobio's corporate tremor attracts Tectonic for reverse merger (FierceBiotech.com) -16.06%
02:38PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL (PR Newswire)
08:00AM	AVROBIO and Tectonic Therapeutic Announce Merger (Business Wire)
Nov-08-23 09:40AM	Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-23-23 09:40AM	Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-06-23 09:40AM	Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-23 07:08AM	AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46% (Zacks)
Jul-12-23 07:00AM	AVROBIO to Explore Strategic Alternatives (Business Wire) +45.96%
Jun-12-23 07:00AM	AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million (Business Wire)
May-22-23 07:00AM	AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million (Business Wire) +69.01%
May-18-23 02:53PM	Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months (Benzinga) +45.33%
07:00AM	AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting (Business Wire)
May-11-23 07:00AM	AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-01-23 07:30AM	AVROBIO Announces Leadership Transition (Business Wire) -15.99%
Mar-23-23 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update (Business Wire) -27.64%
Mar-03-23 07:00AM	AVROBIO to Participate in Cowens 43rd Annual Health Care Conference (Business Wire)
Feb-09-23 07:00AM	AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium 2023 (Business Wire) +7.69%
Jan-05-23 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-07-22 07:30AM	AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy (Business Wire) -6.96%
Nov-17-22 07:00AM	AVROBIO to Share Comprehensive Gaucher Disease Program Update (Business Wire) +5.40%
Nov-08-22 07:00AM	AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-07-22 07:00AM	AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit (Business Wire)
Nov-03-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-27-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire)
Oct-25-22 07:00AM	AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis (Business Wire)
Oct-18-22 07:00AM	AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire) +12.37%
Oct-11-22 07:00AM	AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development (Business Wire)
Oct-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-22 07:00AM	AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress (Business Wire) -10.23%
Sep-20-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis (Business Wire)
Sep-14-22 07:28AM	AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial (Business Wire)
Sep-08-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-22 07:00AM	AVROBIO to Participate in Four Upcoming Investor Conferences in September (Business Wire)
Aug-09-22 07:00AM	AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-22 07:00AM	AVROBIO to Participate in Two Upcoming Investor Conferences in August (Business Wire)
Jul-13-22 07:00AM	AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome (Business Wire)
Jul-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.47%
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -8.57%
12:41PM	Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study (Benzinga)
07:00AM	AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
May-17-22 12:15PM	AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study (Benzinga)
07:00AM	AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures (Business Wire)
May-16-22 07:00AM	AVROBIO to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-10-22 07:00AM	AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-22 07:00AM	AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting (Business Wire)
Apr-06-22 12:36PM	bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn (Zacks)
07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-05-22 12:54PM	Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study (Zacks)
07:00AM	AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-17-22 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update (Business Wire) +8.33%
Mar-01-22 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in March (Business Wire)
Feb-21-22 12:14PM	2 Net Current Asset Value Stocks to Consider (GuruFocus.com)
Feb-09-22 12:55PM	After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data (Benzinga) -6.25%
07:00AM	AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis (Business Wire)
Feb-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks (Zacks)
Feb-01-22 07:00AM	AVROBIO Announces the Appointment of Sean OBryan as Chief Regulatory Officer (Business Wire)
Jan-28-22 07:00AM	AVROBIO to Present at Cowens 2nd Annual Genetic Medicines Summit (Business Wire) +6.32%
Jan-27-22 07:00AM	AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium 2022 (Business Wire) -5.43%
Jan-25-22 10:00AM	Bears are Losing Control Over AVROBIO, Inc. (AVRO), Here's Why It's a 'Buy' Now (Zacks)
Jan-07-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks (Zacks)
Jan-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-22 02:28PM	AvroBio shares plunge after company halts development of Fabry drug (American City Business Journals) -36.63%

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	16.31	53,706	875,945	1,503,358	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	16.73	45,858	767,204	1,449,652	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	14.76	21,071	311,020	1,403,794	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	16.31	9,478	154,586	4,334,846	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	16.73	8,092	135,379	4,325,368	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	14.76	3,718	54,880	4,317,276	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 07 '25	Buy	17.10	412,500	7,053,750	1,382,723	Apr 09 05:38 PM
SPRINGER TIMOTHY A	Director	Apr 07 '25	Buy	17.10	87,500	1,496,250	4,313,558	Apr 09 05:38 PM
MCGUIRE TERRANCE	Director	Apr 07 '25	Sale	17.10	500,000	8,550,000	573,062	Apr 07 05:02 PM
SPRINGER TIMOTHY A	Director	Feb 05 '25	Buy	50.00	660,000	33,000,000	970,223	Feb 07 04:21 PM
SPRINGER TIMOTHY A	Director	Feb 05 '25	Buy	54.14	129,294	6,999,977	4,226,058	Feb 07 04:21 PM
Lochner Daniel	Chief Financial Officer	Feb 05 '25	Buy	54.14	4,617	249,964	4,617	Feb 07 04:19 PM
Schwabish Marc	Chief Business Officer	Jan 28 '25	Option Exercise	2.38	2,700	6,426	4,700	Jan 29 04:05 PM
Schwabish Marc	Chief Business Officer	Dec 09 '24	Option Exercise	2.38	2,000	4,760	2,000	Dec 11 04:21 PM
McNamara Peter	Chief Scientific Officer	Dec 03 '24	Option Exercise	2.38	3,500	8,330	14,188	Dec 05 04:32 PM
SPRINGER TIMOTHY A	Director	Oct 22 '24	Buy	33.59	300,000	10,077,000	4,096,764	Oct 24 05:04 PM
SPRINGER TIMOTHY A	Director	Sep 26 '24	Buy	28.82	50,000	1,440,829	3,796,764	Sep 26 06:15 PM

Open in Screener

IVVD

Invivyd Inc

Aug 18 • 04:00PM ET

0.5811

Dollar change -0.1260
Percentage change -17.82	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX MRK JNJ NVAX AZN GSK GILD SNY

| Held by: VTI VXF PRFZ

Index	-	P/E	-	EPS (ttm)	-0.92	Insider Own	36.51%	Shs Outstand	120.14M	Perf Week	-24.51%
Market Cap	69.81M	Forward P/E	1.43	EPS next Y	0.41	Insider Trans	0.00%	Shs Float	76.28M	Perf Month	-22.26%
Enterprise Value	37.86M	PEG	-	EPS next Q	-0.10	Inst Own	39.54%	Short Float	4.36%	Perf Quarter	-25.18%
Income	-110.13M	P/S	1.51	EPS this Y	69.58%	Inst Trans	-24.14%	Short Ratio	2.67	Perf Half Y	-63.91%
Sales	46.21M	P/B	1.63	EPS next Y	193.10%	ROA	-82.65%	Short Interest	3.33M	Perf YTD	31.14%
Book/sh	0.36	P/C	2.00	EPS next 5Y	-	ROE	-120.08%	52W High	2.74 -78.79%	Perf Year	-40.70%
Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	11.20% -24.99%	ROIC	-246.45%	52W Low	0.35 63.87%	Perf 3Y	-84.50%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	86.23%	Volatility	10.01% 7.85%	Perf 5Y	-
Dividend TTM	-	EV/Sales	0.82	EPS Y/Y TTM	48.93%	Oper. Margin	-245.67%	ATR (14)	0.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.32	Sales Y/Y TTM	1941.08%	Profit Margin	-238.33%	RSI (14)	32.70	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.33	EPS Q/Q	69.13%	SMA20	-23.18%	Beta	0.51	Target Price	4.00
Payout	-	Debt/Eq	0.07	Sales Q/Q	420.58%	SMA50	-23.70%	Rel Volume	2.33	Prev Close	0.71
Employees	99	LT Debt/Eq	0.04	Earnings	Aug 14 AMC	SMA200	-24.29%	Avg Volume	1.25M	Price	0.58
IPO	Aug 06, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2690.70% -54.65%	Trades		Volume	2,903,272	Change	-17.82%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-05-24	Upgrade	Guggenheim	Neutral → Buy	$9
Mar-26-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$4 → $10
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$1 → $4
May-01-23	Initiated	H.C. Wainwright	Buy	$5

Today 04:32PM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") (GlobeNewswire) -17.82%
Aug-14-25 06:00PM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -11.54%
04:49PM	Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
04:47PM	Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 (GlobeNewswire)
Aug-12-25 05:40PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:30AM	Loading…
Aug-08-25 05:30AM	The Race to Find a Measles Treatment as Infections Surge (The Wall Street Journal) +5.88%
Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.10%
Aug-06-25 08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-23-25 07:01AM	Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire) +5.26%
Jul-21-25 07:05AM	National Comprehensive Cancer Network (NCCN) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population (GlobeNewswire)
Jul-02-25 07:01AM	Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire)
Jun-26-25 07:01AM	Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection (GlobeNewswire) +13.43%
Jun-02-25 03:49AM	COVIDs remaining biotech contenders navigate a dwindling market (Pharma Voice)
May-29-25 02:36PM	H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall (Insider Monkey)
May-27-25 07:01AM	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus (GlobeNewswire) +20.15%
07:01AM	Loading…
May-23-25 07:01AM	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas (GlobeNewswire)
May-21-25 09:30AM	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 (GlobeNewswire) -5.52%
May-16-25 03:08AM	Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ... (GuruFocus.com) +10.33%
01:57AM	Q1 2025 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-25 08:15AM	Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -15.78%
07:01AM	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-14-25 09:53AM	What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings (GuruFocus.com)
07:01AM	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy (GlobeNewswire)
May-13-25 07:01AM	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-12-25 07:01AM	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles (GlobeNewswire) +29.67%
May-08-25 07:01AM	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 (GlobeNewswire)
Apr-21-25 09:58AM	What's Going On With Invivyd Stock On Monday? (Benzinga) +10.00%
07:01AM	Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank (GlobeNewswire)
Mar-26-25 04:15PM	Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors (GlobeNewswire) -6.70%
Mar-20-25 09:25AM	Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:01AM	Loading…
08:01AM	Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-12-25 09:40AM	Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? (Zacks)
Mar-05-25 07:05AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 (GlobeNewswire)
Mar-02-25 11:32AM	Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-28-25 12:12PM	Adagio Medical cuts workforce and pauses cryo catheter launch in EU (Medical Device Network) -6.45%
Feb-24-25 07:05AM	FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -29.94%
Feb-18-25 10:27AM	Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far (Insider Monkey) -9.32%
Feb-10-25 07:00AM	Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 (GlobeNewswire) -23.04%
Feb-05-25 09:30AM	Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold (GlobeNewswire) +68.80%
Feb-03-25 07:20PM	Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025 (Insider Monkey) +196.34% +17.92%
07:00AM	Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population (GlobeNewswire)
06:55AM	Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability (GlobeNewswire)
Jan-27-25 07:01AM	Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -12.85%
Jan-10-25 12:12PM	What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday? (Benzinga)
07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC (GlobeNewswire)
Jan-07-25 09:34AM	Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-17-24 06:25AM	Adagio Medical announces Todd Usen as new CEO and director (Medical Device Network) +8.77%
Nov-15-24 03:17AM	Q3 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... (GuruFocus.com)
Nov-14-24 08:20AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.18%
07:05AM	Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
07:01AM	Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor (GlobeNewswire)
Nov-13-24 07:27AM	Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com) -11.00%
Nov-12-24 08:30AM	Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively (GlobeNewswire)
Nov-06-24 08:01AM	Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire) +12.62%
07:01AM	Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 (GlobeNewswire)
Oct-29-24 07:03AM	Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability (GlobeNewswire) -12.80%
07:01AM	Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants (GlobeNewswire)
Oct-16-24 07:01AM	Invivyd to Present PEMGARDA (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 (GlobeNewswire)
Oct-01-24 07:01AM	Invivyd Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data (GlobeNewswire) -11.75%
Sep-23-24 07:01AM	Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA (pemivibart) (GlobeNewswire)
Sep-12-24 07:01AM	Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 (GlobeNewswire) +12.75%
Sep-05-24 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-04-24 07:01AM	Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA (GlobeNewswire)
Sep-03-24 07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest (GlobeNewswire)
Aug-27-24 07:01AM	Invivyd Announces PEMGARDA (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial (GlobeNewswire) -28.67%
Aug-15-24 02:43AM	Q2 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents) +6.12%
Aug-14-24 09:10AM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.55%
08:01AM	Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-12-24 04:01PM	Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -6.31% +9.84%
Jul-01-24 07:01AM	Invivyd Announces its Addition to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) +9.09%
Jun-14-24 07:01AM	Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants (GlobeNewswire) -7.06%
Jun-03-24 04:01PM	Invivyd to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-31-24 07:05AM	Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies (GlobeNewswire)
07:00AM	Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer (GlobeNewswire)
May-29-24 07:00AM	Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC) (GlobeNewswire)
May-22-24 07:00AM	Invivyd Elects Two New Independent Members to its Board of Directors (GlobeNewswire)
May-13-24 04:01PM	Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
10:44AM	Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 03:25PM	Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com) -6.61%
May-09-24 10:56PM	IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024 (InvestorPlace)
04:01PM	Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-07-24 07:30AM	Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback (GlobeNewswire) +6.36%
May-02-24 05:13PM	Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-30-24 07:30AM	Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position (GlobeNewswire) +6.73%
Apr-15-24 07:30AM	Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA (GlobeNewswire)
Apr-12-24 07:30AM	Invivyd Announces CEO Transition (GlobeNewswire)
Apr-04-24 04:01PM	Invivyd Provides PEMGARDA Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million (GlobeNewswire) -8.91% -7.82%
Mar-28-24 01:53PM	IVVD Stock Earnings: Invivyd Misses EPS for Q4 2023 (InvestorPlace) +11.00%
07:00AM	Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-22-24 03:28PM	Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial (GlobeNewswire) +41.10%
03:04PM	Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 (GlobeNewswire)
Feb-05-24 04:02PM	Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 12:35PM	3 Groundbreaking Biotech Stocks to Invest in Now (InvestorPlace) +11.31%
Jan-12-24 12:00PM	All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy (Zacks)
Jan-03-24 07:00AM	Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents (GlobeNewswire)
Dec-23-23 05:29AM	Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy? (Motley Fool)
Dec-19-23 11:52AM	Invivyd (IVVD) Surges on Positive Data From COVID-19 Study (Zacks) -7.52%
Dec-18-23 07:00AM	Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19 (GlobeNewswire) +120.25%
Nov-13-23 10:21AM	Invivyd, Inc. (NASDAQ:IVVD) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.14%

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCGUIRE TERRANCE	Director	Dec 31 '24	Sale	0.45	103,474	46,098	3,066,757	Dec 31 07:16 PM
MCGUIRE TERRANCE	Director	Dec 27 '24	Sale	0.52	83,744	43,647	3,256,776	Dec 31 07:16 PM
MCGUIRE TERRANCE	Director	Dec 30 '24	Sale	0.48	86,545	41,784	3,170,231	Dec 31 07:16 PM
MCGUIRE TERRANCE	Director	Dec 20 '24	Sale	0.42	119,805	50,725	3,568,274	Dec 26 07:46 PM
MCGUIRE TERRANCE	Director	Dec 26 '24	Sale	0.54	83,817	45,563	3,340,520	Dec 26 07:46 PM
MCGUIRE TERRANCE	Director	Dec 24 '24	Sale	0.51	68,161	34,503	3,424,337	Dec 26 07:46 PM
MCGUIRE TERRANCE	Director	Dec 23 '24	Sale	0.45	75,776	34,076	3,492,498	Dec 26 07:46 PM
POLARIS PARTNERS IX, LP	Director	Dec 20 '24	Proposed Sale	0.44	1,000,000	443,900		Dec 20 04:46 PM
MCGUIRE TERRANCE	Director	Dec 19 '24	Sale	0.43	152,067	65,951	3,688,079	Dec 19 05:54 PM
MCGUIRE TERRANCE	Director	Dec 17 '24	Sale	0.48	97,410	46,757	3,914,910	Dec 19 05:54 PM
MCGUIRE TERRANCE	Director	Dec 18 '24	Sale	0.47	74,764	35,087	3,840,146	Dec 19 05:54 PM
MCGUIRE TERRANCE	Director	Dec 12 '24	Sale	0.58	125,000	72,875	4,077,679	Dec 16 08:29 PM
MCGUIRE TERRANCE	Director	Dec 16 '24	Sale	0.47	65,359	30,510	4,012,320	Dec 16 08:29 PM
MCGUIRE TERRANCE	Director	Dec 10 '24	Sale	0.59	175,000	103,005	4,363,079	Dec 11 06:26 PM
MCGUIRE TERRANCE	Director	Dec 11 '24	Sale	0.59	160,400	94,812	4,202,679	Dec 11 06:26 PM
MCGUIRE TERRANCE	Director	Dec 09 '24	Sale	0.61	150,000	91,560	4,538,079	Dec 11 06:26 PM
POLARIS PARTNERS IX, LP	Director	Dec 09 '24	Proposed Sale	0.61	1,000,000	610,400		Dec 09 04:27 PM

Open in Screener

ALEC

Alector Inc

Aug 18 • 04:00PM ET

2.13

Dollar change -0.12
Percentage change -5.33	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN IONS VRTX SGMO SAGE ACAD LLY GILD AVXL

| Held by: IWM VTI IWN VXF IBB SCHA VTWO IWC VHT IWO

Index	RUT	P/E	-	EPS (ttm)	-1.17	Insider Own	24.84%	Shs Outstand	101.21M	Perf Week	-4.48%
Market Cap	215.58M	Forward P/E	-	EPS next Y	-1.16	Insider Trans	-0.78%	Shs Float	76.07M	Perf Month	33.96%
Enterprise Value	-52.22M	PEG	-	EPS next Q	-0.39	Inst Own	63.73%	Short Float	7.47%	Perf Quarter	74.59%
Income	-115.29M	P/S	2.66	EPS this Y	-22.73%	Inst Trans	-2.51%	Short Ratio	6.19	Perf Half Y	25.29%
Sales	81.13M	P/B	3.03	EPS next Y	23.15%	ROA	-24.87%	Short Interest	5.68M	Perf YTD	12.70%
Book/sh	0.70	P/C	0.70	EPS next 5Y	12.57%	ROE	-103.98%	52W High	6.37 -66.56%	Perf Year	-56.17%
Cash/sh	3.04	P/FCF	-	EPS past 3/5Y	-39.73% 6.31%	ROIC	-113.30%	52W Low	0.87 144.83%	Perf 3Y	-83.18%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-21.40% 36.50%	Gross Margin	88.49%	Volatility	13.00% 11.04%	Perf 5Y	-85.16%
Dividend TTM	-	EV/Sales	-0.64	EPS Y/Y TTM	35.46%	Oper. Margin	-160.25%	ATR (14)	0.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.78	Sales Y/Y TTM	46.78%	Profit Margin	-142.10%	RSI (14)	58.76	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.78	EPS Q/Q	23.99%	SMA20	17.16%	Beta	0.98	Target Price	3.83
Payout	-	Debt/Eq	0.55	Sales Q/Q	-47.80%	SMA50	29.26%	Rel Volume	1.51	Prev Close	2.25
Employees	238	LT Debt/Eq	0.43	Earnings	Aug 07 AMC	SMA200	12.25%	Avg Volume	918.04K	Price	2.13
IPO	Feb 07, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.98% 180.73%	Trades		Volume	1,389,913	Change	-5.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-25	Upgrade	Mizuho	Neutral → Outperform	$3.50
Dec-17-24	Downgrade	Mizuho	Outperform → Neutral	$9 → $2.50
Dec-16-24	Downgrade	Stifel	Buy → Hold	$4
Dec-04-24	Downgrade	BofA Securities	Neutral → Underperform	$9 → $1
Nov-29-24	Reiterated	H.C. Wainwright	Buy	$35 → $7
Nov-26-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$10 → $3
Dec-14-23	Upgrade	Stifel	Hold → Buy	$8 → $15
Dec-12-23	Initiated	Deutsche Bank	Buy	$12
Sep-25-23	Initiated	Goldman	Sell	$4
Sep-22-23	Initiated	Cantor Fitzgerald	Overweight	$13
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$24 → $12
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27 → $13
Jul-07-22	Initiated	Mizuho	Buy	$15
Apr-13-22	Initiated	Goldman	Sell	$9
Mar-08-22	Downgrade	Stifel	Buy → Hold	$32 → $18
Sep-27-21	Initiated	William Blair	Outperform
Jan-15-21	Resumed	BofA Securities	Buy	$35
Jun-24-20	Initiated	H.C. Wainwright	Buy	$41
Apr-28-20	Initiated	Goldman	Buy	$32
Mar-06-20	Initiated	Citigroup	Buy	$40

Show Previous Ratings

Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +47.26%
05:09PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 11:40PM	Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation (Insider Monkey) -6.88%
04:05PM	Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call (GlobeNewswire)
04:05PM	Loading…
Jun-13-25 04:05PM	Alector Provides Executive Leadership Update (GlobeNewswire)
Jun-03-25 08:00AM	Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +7.25%
May-13-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.50%
May-08-25 05:30PM	Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +12.50%
04:05PM	Alector Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 08:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire) -9.48%
Apr-21-25 08:50AM	Alector concludes enrolment in Phase II trial of Alzheimers treatment (Clinical Trials Arena) +5.79%
Apr-17-25 08:00AM	Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimers Disease (GlobeNewswire) -5.95%
Mar-28-25 04:05PM	Alector Provides Executive Leadership Update (GlobeNewswire)
Feb-27-25 12:32PM	Q4 2024 Alector Inc Earnings Call (Thomson Reuters StreetEvents)
02:24AM	Loading…
02:24AM	Alector Inc (ALEC) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Feb-26-25 05:55PM	Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:53PM	Alector: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-25 11:01AM	Alector Inc (ALEC) Q4 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
08:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-19-25 04:05PM	Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call (GlobeNewswire)
Jan-13-25 08:00AM	Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025 (GlobeNewswire)
Nov-27-24 06:50AM	Alector price target lowered to $7 from $35 at H.C. Wainwright (TipRanks)
Nov-26-24 09:00AM	Alector stock drops after Alzheimers drug fails in Phase II trial (Clinical Trials Arena) -35.10%
03:44AM	Alector turns to layoffs as Alzheimers drug fails (BioPharma Dive)
Nov-25-24 04:05PM	Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update (GlobeNewswire)
Nov-14-24 04:05PM	Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital (GlobeNewswire) -17.21%
Nov-06-24 05:50PM	Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +7.63%
04:43PM	Alector: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Alector Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Sep-19-24 08:00AM	Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) (GlobeNewswire) +8.87%
Aug-29-24 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-23-24 07:19PM	Director Richard Scheller Sells 44,250 Shares of Alector Inc (ALEC) (GuruFocus.com)
Aug-07-24 06:15PM	Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
05:11PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 04:05PM	Alector to Host Mid-Year Earnings Conference Call (GlobeNewswire)
Jul-28-24 08:05AM	Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference 2024 (AAIC ) (GlobeNewswire)
Jul-23-24 07:00AM	Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference (AAIC ) 2024 (GlobeNewswire)
Jun-29-24 08:43PM	Why Did Analysts Give Alector, Inc. (ALEC) a Moderate Buy Rating? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-20-24 07:00AM	Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-10-24 07:00AM	Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform (GlobeNewswire)
Jun-03-24 07:00AM	Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-09-24 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
May-08-24 11:55PM	ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:25PM	Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:19PM	Alector: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-24 10:02AM	Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know (Zacks) -8.38%
Feb-28-24 02:02PM	Q4 2023 Alector Inc Earnings Call (Thomson Reuters StreetEvents)
10:13AM	Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-27-24 04:46PM	Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +8.18%
04:23PM	Alector: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-20-24 04:05PM	Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call (GlobeNewswire)
10:00AM	Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline (Zacks)
Feb-08-24 07:00AM	Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease (GlobeNewswire)
06:48AM	Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength? (Zacks)
Feb-07-24 07:00AM	FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire) +5.96%
Jan-25-24 12:00PM	Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-23-24 07:32AM	Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs (InvestorPlace)
Jan-19-24 09:20AM	Alector Announces Closing of Public Offering (GlobeNewswire)
Jan-17-24 08:54AM	Alector Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -14.01%
Jan-16-24 04:01PM	Alector Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-08-24 01:25PM	Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 (Investor's Business Daily) +7.34%
Dec-05-23 09:55AM	Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet (Zacks)
Nov-28-23 07:00AM	Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs (GlobeNewswire)
Nov-14-23 09:35AM	Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +14.06%
Nov-08-23 07:00AM	Alector to Participate in the Stifel Healthcare Conference (GlobeNewswire) -7.30%
Nov-07-23 06:02PM	Alector: Q3 Earnings Snapshot (Associated Press Finance) +5.12%
05:11PM	Alector Inc (ALEC) Reports Q3 2023 Financial Results with Key Clinical Advancements (GuruFocus.com)
04:05PM	Alector Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 07:00AM	Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire)
Sep-14-23 01:12AM	10% Owner Polaris Venture Management Co. VI, L.L.C. Sells 500,000 Shares of Alector Inc (GuruFocus.com)
Sep-08-23 12:10PM	Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study (Zacks)
Sep-07-23 07:00AM	Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimers Disease (GlobeNewswire) +6.76%
Aug-31-23 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-10-23 09:55AM	Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade (Zacks)
Aug-03-23 05:45PM	Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +32.38%
04:43PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-23 08:30AM	Alector to Host Mid-Year Earnings Conference Call (GlobeNewswire)
Jul-13-23 01:29PM	7 Stocks That AI Says Will Make You a Millionaire by 2025 (InvestorPlace)
Jun-06-23 07:00AM	Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-01-23 07:29AM	Companies Like Alector (NASDAQ:ALEC) Are In A Position To Invest In Growth (Simply Wall St.) -8.20%
May-09-23 09:55AM	Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect? (Zacks)
May-05-23 06:31AM	Benign Growth For Alector, Inc. (NASDAQ:ALEC) Underpins Its Share Price (Simply Wall St.) +10.27%
May-04-23 07:35PM	Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:27PM	Alector: Q1 Earnings Snapshot (AP Finance)
04:05PM	Alector Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-02-23 07:00AM	Alector to Participate in the BofA Securities 2023 Healthcare Conference (GlobeNewswire)
May-01-23 10:01AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-27-23 10:03AM	Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-13-23 12:59PM	Shareholders in Alector (NASDAQ:ALEC) are in the red if they invested three years ago (Simply Wall St.)
08:30AM	Are Options Traders Betting on a Big Move in Alector (ALEC) Stock? (Zacks)
Mar-01-23 04:05PM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire) -6.36%
Feb-28-23 04:05PM	Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MARC GRASSO	Officer	Aug 08 '25	Proposed Sale	2.00	76,446	152,892		Aug 08 05:22 PM
Yaffe Kristine	Director	Jun 20 '25	Sale	1.44	1,000	1,440	95,409	Jun 23 04:05 PM
GRASSO MARC	Chief Financial Officer	Jun 02 '25	Sale	1.34	16,488	22,068	296,072	Jun 04 04:21 PM
Kenkare-Mitra Sara	President and Head of R&D	Jun 02 '25	Sale	1.34	23,890	31,974	512,252	Jun 04 04:19 PM
Rosenthal Arnon	Chief Executive Officer	Jun 02 '25	Sale	1.34	52,087	69,713	2,414,657	Jun 04 04:18 PM
Sara Kenkare-Mitra	Officer	Jun 02 '25	Proposed Sale	1.33	23,020	30,617		May 30 05:10 PM
Marc Grasso	Officer	Jun 02 '25	Proposed Sale	1.33	15,873	21,111		May 30 05:10 PM
Arnon Rosenthal	Officer	Jun 02 '25	Proposed Sale	1.33	50,242	66,822		May 30 05:10 PM
Kenkare-Mitra Sara	President and Head of R&D	Mar 03 '25	Sale	1.47	29,073	42,662	536,142	Mar 05 04:05 PM
Rosenthal Arnon	Chief Executive Officer	Mar 03 '25	Sale	1.47	40,330	59,176	2,466,744	Mar 05 04:05 PM
GRASSO MARC	Chief Financial Officer	Mar 03 '25	Sale	1.47	18,091	26,547	312,560	Mar 05 04:05 PM
Romano Gary	Chief Medical Officer	Mar 03 '25	Sale	1.47	16,306	23,927	332,977	Mar 05 04:05 PM
Arnon Rosenthal	Officer	Mar 03 '25	Proposed Sale	1.64	50,242	82,397		Feb 28 05:05 PM
Gary Romano	Officer	Mar 03 '25	Proposed Sale	1.64	14,306	23,462		Feb 28 05:05 PM
Sara Kenkare-Mitra	Officer	Mar 03 '25	Proposed Sale	1.64	25,516	41,846		Feb 28 05:05 PM
Marc Grasso	Officer	Mar 03 '25	Proposed Sale	1.64	15,873	26,032		Feb 28 05:05 PM
GRASSO MARC	Chief Financial Officer	Dec 02 '24	Sale	2.52	16,489	41,542	330,651	Dec 03 05:40 PM
Rosenthal Arnon	Chief Executive Officer	Dec 02 '24	Sale	2.52	52,172	131,442	2,507,074	Dec 03 05:40 PM
Kenkare-Mitra Sara	President and Head of R&D	Dec 02 '24	Sale	2.52	26,500	66,764	565,215	Dec 03 05:40 PM
Romano Gary	Chief Medical Officer	Dec 02 '24	Sale	2.52	14,892	37,519	349,283	Dec 03 05:40 PM
Gary Romano	Officer	Dec 02 '24	Proposed Sale	2.59	14,306	37,053		Nov 29 03:00 PM
Sara Kenkare-Mitra	Officer	Dec 02 '24	Proposed Sale	2.59	25,465	65,954		Nov 29 03:00 PM
Marc Grasso	Officer	Dec 02 '24	Proposed Sale	2.59	15,842	41,031		Nov 29 03:00 PM
Arnon Rosenthal	Officer	Dec 02 '24	Proposed Sale	2.59	50,142	129,868		Nov 29 03:00 PM
GRASSO MARC	Chief Financial Officer	Sep 03 '24	Sale	4.88	7,297	35,620	130,740	Sep 04 04:44 PM
Rosenthal Arnon	Chief Executive Officer	Sep 03 '24	Sale	4.88	26,499	129,387	1,948,746	Sep 04 04:15 PM
Kenkare-Mitra Sara	President and Head of R&D	Sep 03 '24	Sale	4.88	13,926	67,981	291,715	Sep 04 04:15 PM
Romano Gary	Chief Medical Officer	Sep 03 '24	Sale	4.88	8,478	41,385	179,795	Sep 04 04:15 PM
Arnon Rosenthal	Officer	Sep 03 '24	Proposed Sale	5.28	24,359	128,616		Aug 30 05:18 PM
Sara Kenkare-Mitra	Officer	Sep 03 '24	Proposed Sale	5.28	12,796	67,563		Aug 30 05:18 PM
Marc Grasso	Officer	Sep 03 '24	Proposed Sale	5.28	6,703	35,392		Aug 30 05:18 PM
Gary Romano	Officer	Sep 03 '24	Proposed Sale	5.28	7,788	41,121		Aug 30 05:18 PM
SCHELLER RICHARD H	Director	Aug 22 '24	Sale	5.16	44,250	228,388	35,000	Aug 23 04:05 PM
SCHELLER RICHARD H	Director	Aug 22 '24	Proposed Sale	4.75	44,250	210,188		Aug 22 05:31 PM

TECX

Tectonic Therapeutic Inc

IVVD

Invivyd Inc

ALEC

Alector Inc

Upgrade your FINVIZ experience